Texas is currently home to 4881 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Cerebellar tDCS in Children With Autism Spectrum Disorder
Recruiting
The purpose of this research study is to investigate whether tDCS to the cerebellum (specifically, the right crus I/II area of the cerebellum) of children and young adults with autism spectrum disorders (ASD) is safe and to examine its effects on some of the symptoms of ASD, such as repetitive behaviors and hyperactivity.
Gender:
ALL
Ages:
Between 4 years and 17 years
Trial Updated:
04/28/2025
Locations: Children's Medical Center, Dallas, Texas
Conditions: Autism Spectrum Disorder
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Recruiting
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Select Advanced Solid Tumors
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Recruiting
This phase II trial studies how well canakinumab works for the treatment of low- or intermediate-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Canakinumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Recruiting
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Clinical Trial Site, Dallas, Texas
Conditions: Generalized Myasthenia Gravis
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recruiting
This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in treating patients with FLT3-mutation positive acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome/myeloproliferative neoplasm that has come back (recurrent) or has not responded to treatment (refractory). Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm
Multiple System Atrophy Multidisciplinary Clinic
Recruiting
This is a prospective cohort study to examine the disease burden of multiple system atrophy and the impact of multidisciplinary care on quality of life and caregiver burden. Data will be collected through valid rating scales completed by patients and caregivers at home or in the MSA clinic.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Multiple System Atrophy (MSA)
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Recruiting
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical q... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Hepatitis B, Hepatitis, Liver Diseases
Heart Attack Research Program- Imaging Study
Recruiting
The HARP study is a multi-center, diagnostic observational study employing standardized imaging protocols in patients with MINOCA (MI with Non Obstructive Coronary Arteries) to determine the underlying diagnosis in each participant. Participants will be followed for recurrent clinical events, every 6 months, for a maximum of 10 years.
Gender:
ALL
Ages:
Between 21 years and 99 years
Trial Updated:
04/28/2025
Locations: Seton Heart (Ascension) Univeristy of Austin, Texas, Austin, Texas
Conditions: Myocardial Infarction
Reducing Dropout and Improving Outcomes From PTSD Therapy: When to Switch Therapies or Stay the Course
Recruiting
Investigators' overall objective is to compare methods of identifying individuals who may be experiencing challenges in Cognitive Processing Therapy (CPT) and compare methods of intervening to optimize treatment retention and outcomes. Investigators' specific aims are: 1. to determine whether the use of CPT skills versus collaboratively considering switching to Present Centered Therapy (PCT) is more effective in improving outcomes for individuals experiencing challenges with CPT. Outcomes inclu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: VA Houston Healthcare System, Houston, Texas
Conditions: Post Traumatic Stress Disorder
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Recruiting
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Clinical Study Site, Austin, Texas
Conditions: Non-Small Cell Lung Cancer
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Recruiting
This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Research Site, Dallas, Texas
Conditions: HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
Recruiting
The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM). The primary objectives of this study are: * To characterize the pharmacokinetics (PK) of GS-4571 following single and multiple ascending oral doses of GS-4571. * To evaluate the effect of concomitant food intake and (if conducted) a representativ... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/25/2025
Locations: ICON Early Phase Services, LLC, San Antonio, Texas
Conditions: Weight Management